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Isolated cells produce insulin-like growth factors (IGFs) and their binding proteins (IGFBPs), Two distinct cell types were studigl with regard to 
IGFBP.2 expression: (i) rat hepatoeytes, which produce IGF l at a high rate and thus regulate its plasma concentration; and (ii) rat osmoblasts, 
which are targets of IGF I action. IGFBP-2 expression is low in hepatocBes prepared from normal adult rat.,s and high in calvaria cells from newborn 
rats, Retinoi¢ acid stimulates IGFBP-2 production by liver cells, Insulin suppresses both basal and retinoic acid.induced IGFBP-2 mRNA 
espression i hepatocytes and has no such effect on osteoblasts, gelinoic acid and insulin regulate IGFBP-2 expression i a tissue-specific manner. 
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I. INTRODUCTION 
Insulin-like growth factors (IGFs) and their binding 
proteins (IGFBPs) are produced by many tissues. Their 
synthesis appears to be regulated by nutritional, ocal 
and endocrine factors [1]. As a result of their affinities 
to IGFs, IGFBPs regulate tissue distribution, half-life 
and actions of IOFs [2]. 
The liver is the main source of serum IGF I [3]. In 
contrast hepatocytes do not appear to produce IGFBP- 
3, the predominant I¢3FBP of serum [4,5]. It is still 
unclear whether the same cell type secretes IGFs and 
IGFBPs in parallel or whether IGFs and IGFBPs are 
released by distinct cell types. Thus it is of interest o 
study regulation of both IGF and IGFBP expression, 
We have previously analysed IGFBPs of conditioned 
media by [l:sI]IOF II ligand blotting, a method which 
detects a variety of IGFBPs, Hepatocytes from adult 
rats released IGFBPs which are distinct from IGFBP- 
3; the release of these (unidentified) IGFBPs was sup- 
pressed by insulin [2,4,6]. Insulin inhibits the expression 
of IGFBP-1 mRNA and the release of the correspond- 
ing protein [7,8]. However, it has not yet been deter- 
mined by the use of specific antibodies whether or not 
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insulin also inhibits IGFBP-2 release by normal adult 
rat hepatocytes. 
In contrast o liver cells ost¢oblasts express tyl~-I 
IOF receptors and are important arget cells of IGF 
action. In addition bone cells produce low amounts of 
IGFs which may act locally, i,¢, as autocrinelparacrin¢ 
factors. We found that calvarial osteoblasts constitu- 
tively expressed much higher IGFBP-2 mRNA levels 
than cultured liver cells. Triiodothyronine increases 
IGFBP-2 mRNA expression in osteoblasts, while reti- 
noic acid (RA) has the opposite ffect [9]. These obser- 
vations prompted us to compare the regulation of 
IGFBP-2 mRNA levels in hepatocytes and osteoblasts 
and to evaluate the relative IGFBP-2 levels in the me- 
dium conditioned by th~s¢ cells using immunoblot anal- 
ysis. 
Insulin has important effects on liver cells via its own 
receptors; it was also tested for effects on ostcoblasts. 
Insulin shares with IOFs an affinity for the type-I IGF 
receptor but not for IGFBPs. Thus it may well affect 
gene expression i  ost¢oblasts but is less likely to inter- 
fere with the secreted IGFBPs. 
Retinoic acid (RA) was used as a model compound 
to modulate geno expression, It has been shown that RA 
stimulates the expression of the phosphoenolpyruvate 
carboxykinase g ne in liver cells [10]; the activity of the 
co.¢sponding enzyme, which is important for hepatic 
g!ueoneogenesis, is down-regulated by insulin. RA is 
teratogenic and has important effects in embryogenesis 
and cell differentiation; RA modulates a variety of 
Publfshed by Elsevier 3cience Publishers B. V. 205 
Volume 303, number 2,3 FEBS LETTERS June 1992 
mRNA levels in osteoblasts [l 1]. Thus  both hepatocytes 
and osteoblasts respond to RA.  
2. MATERIALS  AND METHODS 
2.1. Reagents 
Human monoeomponent i sulin was a gift from Novo-Nordisk 
(Gentofte, DK); it was dissolved in 0.004 N HCi to 100/zg per ml, then 
further diluted in albumin-containing cellculture medium (see below). 
Recombinant human IGF I was a gift from Ciba.Geigy, Basel,, it was 
dissolved in 0.1 M acetic acid at 1 mg per ml. A!btrana-retinolc acid 
(RA) was purchased from Sigma, dissolved at a con~ntration of 2 x 
10 -j M in absolute thanol in subdued light just prior to use, and kept 
in the dark, The aliquots of the stock solutions were diluted in cell 
culture medium to give a final concentration of 0,05% ethanol. The 
ethanol concentration i  the control cultures was adjusted to 0.05%. 
Human serum albumin (HSA) was purchased from the Swiss Red 
Cross and was treated with charcoal to remove fatty acids and steroid 
hormones [12]. 
2.2. Cell culture 
Hepatocytes were prepared from 200 g male adult Sprague-Dawley 
rats by perfasing the liver in situ with bacterial coilagenase as de- 
scribed previously [13] and plated (day 0) at a density of 7 x 10 ~ 
cells/era: on typ¢-I collagen-coated (Serva, Heidelberg, GFR) dishes 
(6 cm diameter, Falcon Primaria) in Williams E medium containing 
fetal calf serum (FCS, 10%), glutamine (2 raM), penicillin (100 U/ml), 
streptomycin (100/~g/ml) (all from Oibco), insulin and dexamethasone 
(both 10 "7 M). 3 h later cells attached, and the medium was replaced 
with fresh medium containing insulin and dexamethasone (10 -~ M 
each) but no FCS. The following day media were replaced with serum. 
and hormone.free medium and incubated for 60 rain at 37"C before 
adding test medium, i.¢. Williams E medium containing 0,2 g/I HSA, 
Osteoblast-like c lls were prepared from newborn rat calvaria nd 
grown in medium containing S% FCS as described elsewhere [14]. 24 
h prior to starting the tast period the cells were rinsed with serum.free 
medium and kept in Williams E medium containing insulin and dex- 
amethasone (both 10 -~ M) and were subsequently treated as described 
for the hepatocytes. 
2,3, Extraction of total RNA and Northern analysis 
2.3.1. RNA preparation 
Upon removal of the culture media for IGFBP analysis (s~ below) 
cells were quickly rinsed 3 times with ice.cold PBS, and collected in 
PBS by scraping them from the dishes with a rubber policeman (the 
material from triplicate wells was pooled) and centrifugation for 10 
rain at 4°C. The pellets were lysed in guanidinium isothiocyanate 
(BRL, Gaithersburg, USA) for preparation of total RNA according 
to Chirgwin [15], and concentrations were measured by measuring UV 
absorbance ata wave length of 260 nm. RNA was stored at -80°C 
until assayed, 
2.3.2. Northern blots 
RNA was denatured (15 rain at 65'C) and equal aliquots (20 ~tg,' 
lane) were size-fractionated in formaldehyde-containing 1% (w/v) aga. 
rose gels, transferred to Nylon filters (Hybond-N, Amersham) by 
capillary blotting, and fixed by UV-crosslinking according to standard 
procedures, 
2.3.3. eDNA probes 
The following eDNAs were used: IGFBP-2 [I 6 l, alkaline phospha- 
tasc (liver/bone/kidney type; [l 7]), 1GF 1 [l 8] and,fl-tubulin [l 9] eDNA. 
InserLs wer~ escire.d from the plasmids and purified by preparative g l 
¢lcctrophor~i~. 0 ng a'..iquots of eDNA were labeled by random 
oligonucleotide priming [20] using a commercial kit (Boehringer) and 
deoxycytidine 5".[c~.a=P]triphosphate (250 #Ci, specific activity 3,000 
Ci/mmol, from Amersham). The radiolabeled DNA probes had spe- 
cific activities of 1-4 x l09 cpm//zg DNA. 
2,3.4, Hybridization procedure 
Prehybridization a d hybridization wen) carried out at 42=C in a 
hybridization incubator (OFL model 7601, Burgwedel, Germany): 
filters were prehybridized in a solution containing 50% (v/v) ofdeion- 
ized formamide, 5 x Denhardt's olution (0.02% Ficoll and 0.02% 
polyvinylpyrrolidon¢), 5 x SSPE (I x SSPE = 0.18 M sodium chloride, 
0.1 M monosodium phosphate, 0.01 M EDTAo pH 7.4), 0.2% SDS and 
100~g/ml of single-stranded sheared salmon sperm DNA, The hybrid- 
ization buffer contained, in addition, about 2 x 107 cpm of hoar- 
denatured [~2P]cDNA probe (1 ng/ml). 
After hybridization for 48 h the membranes were washed in 0.1 x 
SSC/0.1% SDS solution, starting at room temperature and finishing 
with three washes at 54'C (or 45'C as indicated in legends to figures) 
for 20 rain each, and were then exposed at -80'C to an X-brant AR-5 
film (Kodak) in cassettes quipped with intensifying screens to visual- 
ize [~'P]cDNA-mRNA hybrids. 
2.4. Processhzg ofcell culture media nd immunoblot 
Conditioned culture media were collected and processed for im- 
munoblot analysis of IGFBPs, Briefly, media from 3 identically 
treated ishes were pooled and (9 ml)dialyze.d against 0,1 M ammo- 
nium bicarbonate, lyophilized and dissolved in 200/~1 H20 for blot 
analysis of 20 gl sampl~: SDS-PAGE (I 5%) under non-reducing con. 
ditions, transfer to nitrocellulose, and incubation of blots with an 
antiserum raised in rabbits to IGFBP purifi~ from BRL-3A cells, i,e, 
rat IGFBF.2 ([21]; antibody 3695, 1:500) and alkaline phosphatase 
staining using a second antibody (goat anti-rabbit leg alkaline phos. 
phatase conjugate) for det~tion of IGFBP-2, 
3. RESULTS 
Hepatocytes and ostooblasts produce and release 
IGFBPs into the culture medium as assessed by 
[~2Sl]IGF It ligand-blot analysis [2,4,6]. Analysis of 
hepatooyt~a o~taobl~iL~ 
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Fig. 1. IGFBP.2 mRNA in rat hepatoeytes and osteoblasts exposed 
to retinoic acid (RA, 0.1 and 1/~M) and ias~tlin (10 n M) for 24 h, Both 
cell types were handled in parallel for the last 48 h of culture and 
exposed to test media for the last 24 h, as described in section 2. Equal 
amounts of RNA (as confirmed by estimation of ribosomal RNA; 
positions indicated by bars) were analyzed, a.fter hybridization to 
IGFBP-2 eDNA the filter was wash~l at 54~C and exposed to an 
X-ray film ['or detection of IGFBP-2 mRNA. 
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RNA by hybridization to a cDNA specific for IGFBP-2 
revealed marked differences (Fig. I): osteoblasts pre- 
pared from calvariae of newborn rats express high basal 
levels of IGFBP-2; by contrast, IGFBP-2 mRNA is 
barely detectable in RNA from h~patocytes prepared 
from adult rats. IGFBP-2 rnRNA levels are increased 
by RA in hepatocytes but decreased in osteoblasts. RA 
exerts these effects in a dose-dependent manner. Insulin 
inhibits IGFBP-2 mR1NA expression in hepatoeytes but 
does not affect this parameter in bone cells (Fig. 1). 
Under the same conditions (24 h test) IGF  I at 10 nM 
had no effect on IGFBP-2 mRNA expression in both 
hepatocytes and osteoblasts. 
[GFBP-2 mRNA levels are low in hepatocytes freshly 
(A )  fi  culture~l 
Ol~ 2h  6h  24h  - -  
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isolated from normal adult rats. In hepatocytes, time- 
course experiments with 0, 2, 6 and 24 h time points, 
respectively, reveal that the RA-mediated increase of 
IGFBP.2 mRNA levels occurs rapidly and is even more 
pronounced after 24 h. However, the stimulation by RA 
is abolished when insulin is simultaneously present (Fig. 
2A). In contrast, insulin does not affect RA-stimulate, d 
mRNA levels of alkaline phosphatase (Fig. 21}). IGF 1 
mRNA, by contrast, is stimulated by insulin and barely 
affected by RA treatment. As expected, IGF I mRNA 
levels are particularly high in freshly isolated hepato- 
cytes (Fig. 2C). 
Hepatocytes prepared from adult rats and grown in 
primary culture produce large amounts of ICFBPs as 
I O~ 2h  f ih  
RA ÷ + 
Inoulin ÷ + 
~h 
4.  4" ÷ 4" 
÷ 4 ,  + ÷ 
. . . . . .  . . . .  
. . . . , . ,  . := . . . ' . . :~; ,~:~, : . .  
• . ; • .~, ;,:;,!L .~-' 
i 
i" 
• .-" . . .  
.+. 
" ' . ' i  
• . ' . .  
• " . . "  
• . . ' .  




f l  cu lb~'od ,  
Oh  2h  - -  6h  24h  
't" 4, 4" 4" 4. + 
• .I. 4. .Ik 4. 4. 4" 
• . , . . .  . .  " • : .~. . , . - . . .~!  iiiiiii  
Fi& 2. IGFBP-2 (A), alkaline phosplmta~ (B) and IGF I (C) mRNA in freshly isolated rat hepatocytes and during a t~t started (0 h) I day aflcr 
plating: cells were xposed to retinoic acid (RA) and insulin (I0 nM) for 2, 6 and 24 h, resp~tively. Hepatocyms were prepared and ~¢pors:d to
test media (time point 0 h) as d~.-~crib~d; soi~te dishes were, stopp~ imme.diate,ly {0 h), and some a~er 2, 6 and 24 h of incubalion. After hybridization 
to IGFBP-2 eDNA (A), the filter was washed at 45°C. stripped free of IGFBP-2 eDNA, hybridized to alkaline phosphatase (liver/bone/kidney 
tyl~) cD~'.tA and washed at 55°C (B). The filter was also hybridized toIGF I eDNA, washed at 55°C and caposc:d for autoradiography (C). The 
Cxl~riment shown is representative of 4 independent tests. 
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assessed by IGF ligand-blot analysis. However, RNA 
isolated from these cells gives only a weak hybridization 
signal with I(}FBP-2 eDNA (Figs. I and 2) indicating 
that the majority of IGFBPs may not correspond to 
IGFBP.2. Therefore, we looked for IGFBP-2 in the 
conditioned culture medium by means of immunoblots 
with a specific antiserum which had been raised against 
rat IGFBP-2 (Fig. 3). IQFBP-2 is identified at the 32 
kDa protein position in our blot procedure; as it is the 
predominant IOFBP in serum of neonatal (but not 
adult) rats, such serum is shown for comparison i Fig, 
3.  Little IGFBP-2 is detected in media conditioned by 
hepatocytes incubated in control medium (which con- 
tains no protein other than BSA and no hormones), 
RA-trcated hepatocytes release much more IGFBP-2 
into the medium than do control cells (Fig. 3). Another 
prominent band at around 69 kDa is detected by the 
immune serum in all hepatocyte-conditioned m ia and 
also in rat sera. It appears that RA and insulin affected 
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Fig.  3, Immunob lo t  ana lys i s  fo r  IGFBP-2  accumulat ing  in serurn - f r~ 
cu l tur~ med ia  o f  ~dult  rat  hepatocyt~s  cxpose, d to  insu l in  (10 n M)  and  
RA ( I / zM)  fo r  24 h (as  in F igs .  1 and  2) compared  to  IGFBP-2  o f  
n~onaml  rat  senm~ (KS,  2 / l i )  and o f  seL'um-free cu l ture  m~dium 
conditioned by rat osteoblasts (OB) over 24 h. The apparent molecular 
mass of IGFBP-2 is 32 kDa, just above th~ 30 kDa marker (carbonic 
anhydrasc). The 69 kDa marker is albumin, 
the production of IGFBP-2 specifically and markedly 
but the intensity of the 69 kDa band only marginally. 
Moreover, hardly any effect of RA  on IQFBPs is detect- 
able in [~"Sl]IOF II ligand blots of the same culture 
media (not shown). This finding suggests that compara- 
ble amounts of other, more abundant I¢3FBPs are re- 
leased into the medium, irrespective of RA  treatment. 
4. DISCUSSION 
Cultured rat hepatocytes and osteoblasts produce 
and release IOFBP-2 into the medium, as demonstrated 
by hybridization of RNA to a specific eDNA probe, as 
well as by immunoblot analysis of IGFBP-2 in culture 
media. Hepatocytes prepared from adult rats and 
grown in primary culture release several, mainly non- 
glycosylated IGFBPs and very little, if any, IGFBP-3. 
The release of these IQFBPs is suppressed by insulin 
which also inhibits IOFBP-2 mRNA expression [4,6]. 
However, there have been no previous reports howing 
that insulin also decreases I~FBP-2 production of nor- 
mal adult rat hepatocytes in vitro. In addition our data 
show that RA has a specific stimulatory effect on 
IGFBP-2 expression which occurs rapidly and persists 
for at least I day, and that the increased IGFBP-2 
mRNA levels result in increased IGFBP-2 production. 
RA stimulates expression of many mRNA species. Al- 
kaline phosphatase mRNA may serve as an example of 
a RA-indu~d mRNA which is not suppressed by insu- 
lin. Insulin stimulates IGF I mRNA expression [22] 
whereas RA has little effect on this parameter under the 
same conditions (Fig. 2C). RA only regulates IGFlaP-2 
and has no detectable effect on other IGFBPs indicating 
that this effect of RA is specific. Since the effect of  RA 
is of considerable magnitude by immunoblot analysis 
but barely detectable on the [12sI]IOF II ligand blot it 
is likely that IGFBP-2 constitutes only a minor percent- 
age of total IGFBPs released by hepatocytes, at least 
when they are kept without RA. These other, as yet 
unidentified IGFBPs have a molecular weight compara- 
ble to that of IGFBP-2 so that the ligand blot cannot 
be used to quantitate changes of IGFBP-2. IGFBP-2 
mRNA levels correlate with the amount of  IGFBP.2 in 
the medium: (i) osteoblasts express higher mRNA levels 
and produce more IGFBP-2 than hepatocytes; (ii) RA 
induces and insulin inhibits both IOFBP-2 mRNA and 
IGFBP-2 release in hepatocytes. 
Insulin suppresses basal [6] and RA-induced (Fig. 2) 
ICIFBP-2 mRNA levels in hepatocytes. Since basal 
IGFBP-2 mRNA levels are low and increase slowly in 
insulin-deprived ( e-differentiating) hepatocytes, the in- 
hibitory effect of insulin is more pronounced in RA- 
exposed hepatocyte cultures (Fig. 2). RA  permits easier 
det~tion of the !GFBP-2 suppression by insulin at both 
the mRNA and protein level. The regulation of IQFBP- 
2 by insulin is specific for hepatocytes. In ostecblasts 
insulin, as well as I(}F I, failed to affect IOFBP.2 
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mRNA levels. At the same time IGF I, but not insulin, 
stimulated the accumulation of a 32 kDa IGFBP in 
osteoblast culture medium, recently identified as 
IGFBP-2 (C.S. and J.g., in preparation); this difference 
between insulin and IGF may indicate that increased 
IGFBP-2 accumulation i media of IGF-treated os- 
teoblasts is due to stabilization of released IGFBP 
rather than to an effect on IGFBP-2 synthesis. 
We have previously reported that increased hepatic 
IGFBP-2 expression i  vivo is usually observed in con- 
ditions characterized by low insulin secretion such as 
streptozotocin-induced diabetes in rats and in extrapan- 
creatic turnout hypoglycemia, nd during IGF I treat- 
ment in humans [4,23,24]. These findings are compati- 
ble with our present observations on cultured hepato- 
cytes. 
IGF and IGFBP production are modulated by 
hormones in a specific manner at the level of their target 
tissues. Insulin is an important negative regulator of 
IGFBP-2 production in liver but not in bone cells. RA 
and, less effectively, triodothyronine (not shown) posi- 
tively regulate IGFBP-2 mRNA expression in hepato- 
cytes. In analogy, triiodothyronine is also less potent 
than RA in inducing the expression of the 
phosphoenolpyruvate carboxykinase gene in an adult 
rat hepatocyte cell line [10]. The latter en~me is rate- 
limiting for hepatic gluconeogenesis and is also down- 
regulated by insulin. Thus, the regulation of PEPCK 
and IGFBP-2 mRNA expression in liver cells share 
common features. However, in contrast o the well- 
known function of PEPCK the physiological role of 
IGFBP-2 is not understood. 
RA is the most potent naturally occurring retinoid. 
Difficulties in measuring tissue concentrations contrib- 
uted to the reluctance to accept RA as an endogeneous 
humeral agent. By using improved methodology, its 
tissue concentrations can now be estimated to range 
from 0.02-0.6 ,aM [25]. 
RA plays a role in growth, differentiation and malig- 
nancy. Thus RA induces differentiation of embryonic 
stem cells such as the routine F9 teratocarcinoma cell 
line; in this particular cell line RA also induces bone/ 
liver/kidney-type alkaline phosphatase [26]. RA also 
stimulates differentiation and alkaline phosphatase ex- 
pression in undifferentiated bone cell lines [27,28] but 
not in our osteoblast ystem (not shown). Our observa- 
tions may provide a model to further study the cell- 
specific control of IGFBP gene expression in vitro and 
suggest autocrine/paracrine functions of IGFBPs. 
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